Compass Pathways plc has released a new investor presentation highlighting recent progress in its clinical development programs for mental health indications, including treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). The company’s proprietary synthetic psilocybin formulation, COMP360, is currently being evaluated in the largest ongoing pivotal trial of a classic psychedelic, with Phase 3 COMP005 results demonstrating a statistically significant and clinically meaningful reduction in TRD symptom severity compared to placebo. The Data Safety Monitoring Board reported no unexpected safety findings for COMP360. Additional data from the ongoing COMP005 and COMP006 trials are expected in 2026. Compass Pathways reported a cash position of $186 million as of September 30, 2025, and anticipates its funding will support operations into 2027. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Compass Pathways plc published the original content used to generate this news brief on January 07, 2026, and is solely responsible for the information contained therein.